Tafamidis

NERVOUS SYSTEM

Key facts

Tafamidis is an onp drug catalogued in DrugCentral. It was first approved by the EMA in 2011. DrugCentral lists 4 molecular targets, including TTR, ABCG2 and SLC22A8. Recorded indications include Amyloid polyneuropathy type I, Amyloidosis, Transthyretin related familial amyloid cardiomyopathy and Wild-type transthyretin cardiac amyloidosis.

• Approval status: onp (first approved 2011 by the EMA).
• Molecular targets: TTR, ABCG2, SLC22A8 and SLC22A6 (4 listed in DrugCentral).
• Indications: Amyloid polyneuropathy type I, Amyloidosis, Transthyretin related familial amyloid cardiomyopathy and Wild-type transthyretin cardiac amyloidosis.
• ATC code: N07XX08 (Other nervous system drugs).
• Molecular formula: C14H7Cl2NO3; molecular weight 308.11 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Amyloid polyneuropathy type I
• Amyloidosis
• Transthyretin related familial amyloid cardiomyopathy
• Wild-type transthyretin cardiac amyloidosis

Mechanism & targets

Molecular targets (4)

Target	Gene	Action	Activity
Transthyretin	TTR	other	Kd 6.81
ATP-binding cassette sub-family G member 2	ABCG2	inhibitor	IC50 5.94
Solute carrier family 22 member 8	SLC22A8	inhibitor	IC50 5.63
Solute carrier family 22 member 6	SLC22A6	inhibitor	IC50 5.54

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2019-03-05	FDA	—	FOLDRX PHARMS	Yes
2013-09-20	PMDA	—	PFIZER	Yes
2011-11-16	EMA	—	—	Yes

ATC classification

ATC code	Therapeutic hierarchy
N07XX08	NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › OTHER NERVOUS SYSTEM DRUGS › Other nervous system drugs

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: TTR
• FDA label: TTR
• HCSC label: TTR

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Death	3453.1
Cardiac failure	1859.9
Cardiac failure chronic	1009.9
Cardiac amyloidosis	472.7
Atrial fibrillation	470.6
Cardiac failure congestive	188.5
Disease progression	172.6
Left ventricular hypertrophy	165.7
Amyloidosis	141.1
Dyspnoea exertional	134.6
Dyspnoea	128.0
N-terminal prohormone brain natriuretic peptide increased	124.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Tafamidis is on its molecule page.

• Molecular formula: C₁₄H₇Cl₂NO₃
• Molecular weight: 308.11 g/mol
• CAS number: 594839-88-0
• InChIKey: TXEIIPDJKFWEEC-UHFFFAOYSA-N
• PubChem CID: 11001318

OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Tafamidis used for?

DrugCentral lists the following indications for Tafamidis: Amyloid polyneuropathy type I, Amyloidosis, Transthyretin related familial amyloid cardiomyopathy and Wild-type transthyretin cardiac amyloidosis.

How does Tafamidis work?

Its molecular targets in DrugCentral include TTR, ABCG2 (inhibitor), SLC22A8 (inhibitor) and SLC22A6 (inhibitor).

When was Tafamidis first approved?

Tafamidis was first approved by the EMA in 2011.

What is the chemical formula of Tafamidis?

Tafamidis has the molecular formula C14H7Cl2NO3 and a molecular weight of 308.11 g/mol.

Sources

• DrugCentral drug card 4192 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2103837 — compound record and bioactivity
• PubChem CID 11001318 — chemical identifiers
• DrugBank DB05352 — drug record
• FDA UNII 8FG9H9D31J — substance identity
• DailyMed: FDA labels for Tafamidis — current prescribing information (label search)
• UniProt P02766 (TTR) — target protein
• UniProt Q9UNQ0 (ABCG2) — target protein
• UniProt Q8TCC7 (SLC22A8) — target protein
• UniProt Q4U2R8 (SLC22A6) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.